Hogan Lovells advises Valneva regarding its purchase agreement with Bahrain for its inactivated Covid-19 vaccine candidate, VLA2001

Valneva is a company specializing in the development and commercialization of prophylactic vaccines against infectious diseases with high medical needs. The Group has leveraged its expertise and infrastructure to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates in clinical development, including those against Lyme disease, chikungunya virus and Covid-19.

This transaction represents the second agreement signed by Valneva for VLA2001, following the advanced purchase agreement signed with the European Commission last month after the announcement of positive results for its Phase 3 "Cov-Compare" clinical trial.

Under the terms, Valneva could supply 1 million doses of its vaccine to the Kingdom of Bahrain. Deliveries could begin in the first quarter of 2022, provided Valneva obtains marketing authorization from the Bahraini health agency NHRA.

Following the signing of this agreement and such authorization, Valneva will be able to contribute to the fight against the current pandemic in the Middle East.

The Hogan Lovells team was led by Jean-Marc Franceschi (partner), Mikael Salmela (partner), Maimouna Goudiaby (senior associate) and Daghan Ozturk (associate).